Table 1A.

Incidence rates and risks of heart failure in groups treated with ustekinumab or anti‐tumour necrosis factor‐α inhibitors after IPTW

	Number	Event	Person‐years	IR a	HR (95% CI)	P‐value
HF outcome
Anti‐TNF‐α inhibitor	2020	45.145	4024.42	11.218	1 [reference]	0.0426
Ustekinumab	2448	38.521	5466.82	7.046	0.641 (0.415–0.985)

CI, confidence interval; HF, heart failure; HR, hazard ratio; IPTW, inverse probability of treatment weighting; IR, incidence rate; TNF‐α, tumour necrosis factor‐α.

^a Per 1000 person‐years.